Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sangamo Biosciences ( (SGMO) ) has shared an update.
On June 24, 2025, Sangamo Therapeutics, Inc. announced positive topline results from its Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease. The study showed significant improvements in kidney function and quality of life measures, with a favorable safety profile. These results support the potential of isaralgagene civaparvovec as a one-time treatment for Fabry disease, paving the way for a Biologics Licensing Application under the Accelerated Approval pathway by early 2026.
The most recent analyst rating on (SGMO) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.
Spark’s Take on SGMO Stock
According to Spark, TipRanks’ AI Analyst, SGMO is a Underperform.
Sangamo Biosciences’ overall stock score is heavily impacted by its poor financial performance and bearish technical indicators, which highlight significant risks. While there are some positive developments in partnerships and clinical advancements, these are overshadowed by immediate financial challenges and valuation concerns. The potential delisting notice from Nasdaq further adds to the uncertainty.
To see Spark’s full report on SGMO stock, click here.
More about Sangamo Biosciences
Average Trading Volume: 6,652,462
Technical Sentiment Signal: Sell
Current Market Cap: $112.3M
See more insights into SGMO stock on TipRanks’ Stock Analysis page.